From 2018 to 2022, the overall death rate for lung and bronchus cancer in the Kentucky was 61 per 100,000 for males and 43.2 per 100,000 for females. This statistic presents the death rates for lung and bronchus cancer in the United States from 2018 to 2022, by state and gender.

The interannual variability of SMR for a given administrative unit might be large under small populations. Indeed, being the SMR a rate standardized over the population size, the expected mortality (i.e., Em) in small populations will result low (say 10-2) and in turn, according to eq. (1), even a few deaths (say 1 or 2) in a year could yield a relatively high SMR as shown in Figure 3. For this reason, we recommend avoiding using single-year estimates and using the average SMR and/or lower 90% or 95% confidence intervals.

This statistic shows the share of total survivals from childhood cancer in Sweden in 2018, by type. The highest share of children who survived childhood cancer were children with leukemia. Children ill with leukemia composed ** percent of the total childhood cancer survival in Sweden in 2018.

This release summarises the survival of adults diagnosed with cancer in England between 2015 and 2019 and followed to 2020, and children diagnosed with cancer in England between 2002 and 2019 and followed to 2020. Adult cancer survival estimates are presented by age, deprivation, gender, stage at diagnosis and geography. Update 8th June 2022: We have now published an additional ODS data file ‘Cancer Survival in England Back Series, cancers diagnosed from 2006 to 2018: Adults’. This publication presents a back series of 1- to 5-year net survival for adults (15 to 99 years) diagnosed with cancer between 2006 to 2018 (5-year rolling cohorts). This back series was completed due to a change in methodology in the most recent publication (Cancers diagnosed between 2015 and 2019) to allow for comparison of net survival estimates over time.

In the period 2018 to 2022, a total of approximately *** men per 100,000 inhabitants died of cancers of all kinds in the United States, compared to an overall cancer death rate of *** per 100,000 population among women. This statistic shows cancer death rates in the U.S. for the period from 2018 to 2022, by type and gender.

This dataset includes information regarding survival for children (aged 0 to 14 years) diagnosed with cancer in England from 1990 to 2018, followed up to 31 December 2018. The analyses were carried out using the cohort, period and hybrid approaches.

It was estimated that in 2018 there were ** cervical cancer deaths per 100,000 women in Southern Africa. Most cervical cancer cases are due to human papillomavirus (HPV), which is the most common sexually transmitted infection worldwide.

BackgroundCervical cancer incidence and mortality rates in the United States have substantially declined over recent decades, primarily driven by reductions in squamous cell carcinoma cases. However, the trend in recent years remains unclear. This study aimed to explore the trends in cervical cancer incidence and mortality, stratified by demographic and tumor characteristics from 1975 to 2018.MethodsThe age-adjusted incidence, incidence-based mortality, and relative survival of cervical cancer were calculated using the Surveillance, Epidemiology, and End Results (SEER)-9 database. Trend analyses with annual percent change (APC) and average annual percent change (AAPC) calculations were performed using Joinpoint Regression Software (Version 4.9.1.0, National Cancer Institute).ResultsDuring 1975–2018, 49,658 cervical cancer cases were diagnosed, with 17,099 recorded deaths occurring between 1995 and 2018. Squamous cell carcinoma was the most common histological type, with 34,169 cases and 11,859 deaths. Over the study period, the cervical cancer incidence rate decreased by an average of 1.9% (95% CI: −2.3% to −1.6%) per year, with the APCs decreased in recent years (−0.5% [95% CI: −1.1 to 0.1%] in 2006–2018). Squamous cell carcinoma incidence trends closely paralleled overall cervical cancer patterns, but the incidence of squamous cell carcinoma in the distant stage increased significantly (1.1% [95% CI: 0.4 to 1.8%] in 1990–2018). From 1995 to 2018, the overall cervical cancer mortality rate decreased by 1.0% (95% CI: −1.2% to −0.8%) per year. But for distant-stage squamous cell carcinoma, the mortality rate increased by 1.2% (95% CI: 0.3 to 2.1%) per year.ConclusionFor cervical cancer cases diagnosed in the United States from 1975 to 2018, the overall incidence and mortality rates decreased significantly. However, there was an increase in the incidence and mortality of advanced-stage squamous cell carcinoma. These epidemiological patterns offer critical insights for refining cervical cancer screening protocols and developing targeted interventions for advanced-stage cases.

One-year and five-year net survival for adults (15-99) in England diagnosed with one of 29 common cancers, by age and sex.

Description

The Cancer Imaging Archive (TCIA) has procured substantial troves of image data, which could serve as valuable training sets for improving machine learning algorithms. However, these datasets lack consistent lesion annotations. To address this issue, the Cancer Imaging Informatics Lab at the Frederick National Laboratory for Cancer Research (FNLCR) formed a partnership with five groups funded by the National Cancer Institute's Informatics Technology for Cancer Research program to develop a web-based crowdsourcing application for gathering lesion annotations, featured at the annual meeting of the Radiological Society of North American (RSNA). Crowds Cure Cancer (https://www.crowds-cure.org) first exhibited at RSNA 2017 utilizing CT scans from 4 different TCIA collections. Participants were asked to make a uni-dimensional measurement of the largest lesion. There were no options to provide details regarding imaging quality (e.g., no IV contrast, motion artifact, etc.), lesion location (e.g., lung, liver, etc.) or lesion characteristics (e.g., ill-defined, ground glass, etc.), requiring additional post-collection image review. The Crowds-Cure-2017 dataset can be found at DOI: 10.7937/K9/TCIA.2018.OW73VLO2. For RSNA 2018, the application was re-designed to promote more comprehensive data collection and increased community participation. Participants were instructed to identify all metastatic disease and provide details regarding image quality, lesion location and characteristics. To provide additional incentives for participation, we improved the system by adding gamification features (e.g., reward badges), and created a leaderboard to display participant standings. The amount of data being annotated was also significantly increased to include CT scans from 324 patients spanning 13 TCIA collections: Anti-PD-1_Lung, Anti-PD-1_MELANOMA, CPTAC-CCRCC, CPTAC-GBM, CPTAC-HNSCC, CPTAC-PDA, CPTAC-UCEC, NSCLC Radiogenomics, TCGA-BLCA, TCGA-COAD, TCGA-HNSC, TCGA-LUSC, TCGA-UCEC. During RSNA 2018, 4756 bi-directional measurements were obtained compared to 2345 uni-dimensional measurements in 2017. Of the 4756 measurements, 65% of the lesions were annotated with location information. The data is being released in DICOM Structured Report and CSV formats for analysis by the community. The application is available on GitHub https://github.com/crowds-cure/cancer .

ObjectiveThe approval of immunotherapy (I-O) for the treatment of late-stage non-small cell lung cancer (NSCLC) opened new perspectives in improving survival outcomes. However, survival data have not yet been provided from the period of the Covid-19 pandemic. The aims of our study were to assess and compare survival outcomes of patients with advanced LC receiving systemic anticancer treatment (SACT) before and after the approval of immunotherapy in Hungary, and to examine the impact of pandemic on survival outcomes using data from the Hungarian National Health Insurance Fund (NHIF) database.MethodsThis retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with advanced stage lung cancer (LC) (ICD-10 C34) between 1 January 2011 and 31 December 2021 and received SACT treatment without LC-related surgery. Survival rates were evaluated by year of diagnosis, sex, age, and LC histology.ResultsIn total, 35,416 patients were newly diagnosed with advanced LC and received SACT during the study period (mean age at diagnosis: 62.1–66.3 years). In patients with non-squamous cell carcinoma, 3-year survival was significantly higher among those diagnosed in 2019 vs. 2011–2012 (28.7% [95% CI: 26.4%–30.9%] vs. 14.45% [95% CI: 13.21%–15.69%], respectively). In patients with squamous cell carcinoma, 3-year survival rates were 22.3% (95% CI: 19.4%–25.2%) and 13.37% (95% CI: 11.8%–15.0%) in 2019 and 2011–2012, respectively, the change was statistically significant. Compared to 2011–2012, the hazard ratio of survival change for non-squamous cell carcinoma patients was 0.91, 0.82, and 0.62 in 2015–2016, 2017–2018, and 2019, respectively (p<0.001 for all cases). In the squamous cell carcinoma group, corresponding hazard ratios were 0.93, 0.87, and 0.78, respectively (p<0.001 for all cases). Survival improvements remained significant in both patient populations during the Covid-19 pandemic (2020–2021). No significant improvements were found in the survival of patients with small cell carcinoma. Platinum-based chemotherapy was the most common first-line treatment in all diagnostic periods, however, the proportion of patients receiving first- or second-line immunotherapy significantly increased during the study period.Conclusion3-year survival rates of NSCLC almost doubled among patients with non-squamous cell carcinoma and significantly improved at squamous cell carcinoma over the past decade in Hungary. Improvements could potentially be attributable by the introduction of immunotherapy and were not offset by the Covid-19 pandemic.

Average case fatality ratio (%) over the period 2007–2018 by region.

This dataset includes information regarding Cancer survival in England where adults aged 15 to 99 were diagnosed between 2013 and 2017 and followed up to 2018. When the data for this report were extracted for analysis on 11 August 2019, cancer registrations in 2017 were believed to be at least 98% complete, and the vital status for each patient at 31 December 2017 was known for at least 99% of cancers registered between 2013 and 2017.

Objective: While Hungary is often reported to have the highest incidence and mortality rates of lung cancer, until 2018 no nationwide epidemiology study was conducted to confirm these trends. The objective of this study was to estimate the occurrence of lung cancer in Hungary based on a retrospective review of the National Health Insurance Fund (NHIF) database.Methods: Our retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with lung cancer (ICD-10 C34) between 1 Jan 2011 and 31 Dec 2016. Age-standardized incidence and mortality rates were calculated using both the 1976 and 2013 European Standard Populations (ESP).Results: Between 2011 and 2016, 6,996 – 7,158 new lung cancer cases were recorded in the NHIF database annually, and 6,045 – 6,465 all-cause deaths occurred per year. Age-adjusted incidence rates were 115.7–101.6/100,000 person-years among men (ESP 1976: 84.7–72.6), showing a mean annual change of − 2.26% (p = 0.008). Incidence rates among women increased from 48.3 to 50.3/100,000 person-years (ESP 1976: 36.9–38.0), corresponding to a mean annual change of 1.23% (p = 0.028). Age-standardized mortality rates varied between 103.8 and 97.2/100,000 person-years (ESP 1976: 72.8–69.7) in men and between 38.3 and 42.7/100,000 person-years (ESP 1976: 27.8–29.3) in women.Conclusion: Age-standardized incidence and mortality rates of lung cancer in Hungary were found to be high compared to Western-European countries, but lower than those reported by previous publications. The incidence of lung cancer decreased in men, while there was an increase in incidence and mortality among female lung cancer patients.

From 2012 to 2018, for any stage of colorectal cancer, Asian and Pacific Islanders had a five-year survival rate of about 64 percent. This statistic displays the percentage of affected colorectal cancer patients that had survived for at least five years after their initial diagnosis from 2012 to 2018, by stage at diagnosis and race/ethnicity.

Age-standardized incidence-based mortality rates, and annual percent changes in primary liver cancer rates, 1978–2018.

Breast cancer is a leading cause of illness and death among women in Chile, yet national data on health outcomes remain limited in the absence of a cancer registry. This observational study examines disparities in breast cancer case fatality ratios and survival rates by health insurance provider and geographic region using national hospital discharge and mortality databases from 2007 to 2018. We analyzed 58,254 hospital discharges and 16,615 deaths related to breast cancer. Case fatality and survival estimates were computed using crude ratios, Kaplan-Meier methods, and Cox proportional hazards models. Nationally, the average case fatality ratio was 26.8 percent. Patients in the public health insurance system had significantly higher fatality ratio (27.5 percent) than those in the private system (15.7 percent). One- and five-year survival rates were lower for publicly insured patients (93.4 percent and 80.8 percent) than for privately insured patients (97.3 percent and 90.2 percent). Within the public system, survival varied by income-based segment, with the lowest rates among the most socioeconomically disadvantaged group. Patients in the Metropolitan Region showed better survival compared to those living in other regions. Cox regression analysis confirmed that health insurance type, age, year of diagnosis, and region of residence were significant predictors of survival. These findings suggest that, despite universal health guarantees in Chile, meaningful inequities in breast cancer outcomes persist. The methodology used in this study relies on administrative data and can be applied in other countries or regions with access to comparable hospital discharge and mortality records, supporting broader efforts to monitor and reduce healthcare disparities.